Home > Boards > US OTC > Telecommunications Networks > Central Wireless Inc. (CWIR)

CWIR board/director David Platt OXYGEN THERAPY board members..... stunning

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
1234zxcv Member Profile
Followed By 270
Posts 13,559
Boards Moderated 0
Alias Born 06/11/11
160x600 placeholder
1234zxcv   Friday, 10/06/17 10:31:40 AM
Re: Backstabbed post# 31829
Post # of 48165 
CWIR board/director David Platt OXYGEN THERAPY board members.....stunning LEGIT....
David Platt, Ph.D.
CEO/Chairman of the Board
Platt is a world-renowned
expert in carbohydrate chemistry
and has founded three publiclytraded
companies, creating nearly
$1B for investors. Prior to Boston
Therapeutics, (OTC: BTHE) from
2001 to 2009, Dr. Platt was a
founder, Chief Executive Officer
and Chairman of the Board at ProPharmaceuticals,
From 1995 to 2000 Dr. Platt was
the founder of International Gene

Yuval Kwintner
President & Board Member
An experienced entrepreneur and
business executive with proven
abilities in both established
organizations and start-up
ventures. Earned an MBA from
MIT Sloan School of Management,
a B.Sc. from the Technion - Israel
Institute of Technology, and an
LL.B. (JD equivalent) from Tel Aviv

Dr. Ben-Zion Weiner, PhD

Dr. Ben-Zion Weiner was Head of Global
Research and Development at Teva
Pharmaceutical Industries Ltd. for over three
decades, including as a member of the Teva
Executive Committee. He directly oversaw all
pharmaceutical development and regulatory
approval of Teva’s innovative product pipeline.
Dr. Weiner was also responsible for the
development of hundreds of generic products
for the US, European, and other markets
. He
received a BSc degree in general chemistry
and biochemistry and an MSc degree in
organic chemistry, graduating with distinction
for both degrees from the Hebrew University,
Jerusalem. He received his PhD degree in
chemistry at the Hebrew University,
Jerusalem, and conducted his post-doctoral
research at Schering-Plough Corporation in
the United States.

Hana Chen-Walden, M.D.
Medical Advisory Board Chairman
Dr. Chen-Walden is an Endocrinologist and
has specialized in regulatory affairs in the
pharmaceutical industry in the U.S and
Europe. Dr. Chen-Walden has more than
35 years of regulatory experience with the
EMEA and in individual European Dr. Chen
Walden received her Doctorate of
Medicine from University of Tel Aviv, Israel.
Dr. Chen-Walden has practiced medicine in
Germany and France

Benjamin Rivnay, Ph.D.
Chief Scientist Director of R&D at Formatech
Managed 50+ projects on formulation
development Vice President, R&D and Lab
Director at Repromedix: Introduced over 50
new test products Senior Investigator and
Program Leader at Procept: Initiated and led
R&D programs Senior Scientist at Neurex
Corporation Associate Professor of
Biochemistry Ph.D., Biochemistry,
Weizmann Institute of Science; B.Sc.,
Biology, Tel Aviv University

Ache Stokelman, B.S.
Senior Advisor
Ache is a veteran of the Biotech industry. He
spent over 20 years at Amgen where he
invented, developed and deployed new
technologies and methods for Process
Development. Earlier in his career he
designed, build and troubleshoot safety and
control systems on offshore platforms. He
obtained a BS in Mechanical Engineering at
The Technion Institute of Technology, Israel

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist